Bone Biologics (NASDAQ:BBLG), Inc. (NASDAQ:BBLG) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for bone regeneration and orthopedic applications. Leveraging proprietary recombinant human bone morphogenetic protein (rhBMP) technology, the company aims to address unmet needs in spinal fusion, fracture repair, dental bone grafting and other musculoskeletal conditions. Bone Biologics conducts research and preclinical development to advance its lead candidates through regulatory pathways toward commercialization.
The company’s product pipeline features multiple programs designed to offer safer and more effective alternatives to existing bone graft materials. Its lead candidate, OPM-105, is an rhBMP-based fusion product intended to promote bone growth in spinal fusion procedures with a potentially lower side-effect profile compared to first-generation BMP therapies. In parallel, Bone Biologics is advancing OPM-201 for long-bone healing and OPM-301 for dental and maxillofacial applications, each engineered to optimize delivery and osteoinductive performance.
Bone Biologics maintains operations in the United States with collaborative partnerships in Europe and Asia to support clinical development and regulatory filings across key markets. The company works closely with academic medical centers, contract research organizations and distribution partners to facilitate clinical trials and lay the groundwork for commercial launch. Its multidisciplinary team encompasses expertise in protein engineering, material science and orthobiologics commercialization strategies.
Since its inception, Bone Biologics has been led by a management team with deep experience in regenerative medicine and orthopedic drug development. The company’s executives, including CEO Kathryn Simmons and Chief Scientific Officer Dr. Michael Torres, bring prior track records of advancing biologic candidates through clinical milestones and successful out-licensing deals. Guided by a commitment to improving patient outcomes, Bone Biologics continues to expand its scientific platform and engage with key opinion leaders in the orthopedic community.
